Display options
Cite
Chagas CM, Alisaraie L. Metabolites of Vinca Alkaloid Vinblastine: Tubulin Binding and Activation of Nausea-Associated Receptors. ACS Omega. 2019;4(6):9784-9799doi: 10.1021/acsomega.9b00652.
Chagas, C. M., & Alisaraie, L. (2019). Metabolites of Vinca Alkaloid Vinblastine: Tubulin Binding and Activation of Nausea-Associated Receptors. ACS omega, 4(6), 9784-9799. https://doi.org/10.1021/acsomega.9b00652
Chagas, Caroline Manto, and Alisaraie, Laleh. "Metabolites of Vinca Alkaloid Vinblastine: Tubulin Binding and Activation of Nausea-Associated Receptors." ACS omega vol. 4,6 (2019): 9784-9799. doi: https://doi.org/10.1021/acsomega.9b00652
Chagas CM, Alisaraie L. Metabolites of Vinca Alkaloid Vinblastine: Tubulin Binding and Activation of Nausea-Associated Receptors. ACS Omega. 2019 Jun 04;4(6):9784-9799. doi: 10.1021/acsomega.9b00652. eCollection 2019 Jun 30. PMID: 31460070; PMCID: PMC6648052.
Copy Download .nbib Format: NLM
Share it on

ACS Omega. 2019 Jun 04;4(6):9784-9799. doi: 10.1021/acsomega.9b00652. eCollection 2019 Jun 30.

Metabolites of Vinca Alkaloid Vinblastine: Tubulin Binding and Activation of Nausea-Associated Receptors.

ACS omega

Caroline Manto Chagas, Laleh Alisaraie

Affiliations

  1. School of Pharmacy, Memorial University of Newfoundland, 300 Prince Philip Dr., A1B 3V6 St. John's, Newfoundland, Canada.
  2. Department of Chemistry, Memorial University of Newfoundland, A1B 3X7 St. John's, Newfoundland, Canada.

PMID: 31460070 PMCID: PMC6648052 DOI: 10.1021/acsomega.9b00652

Abstract

Vinblastine (VLB) is an antimitotic drug that binds to the vinca site of tubulin. The molecule possesses a high molecular weight and a complex chemical structure with many possibilities of metabolization. Despite advances in drug discovery research in reducing drug toxicity, the cause and mechanism of VLB-induced adverse drug reactions (ADRs) remains poorly understood. VLB is metabolized to at least 35 known metabolites, which have been identified and collected in this present work. This study also explores how VLB metabolites affect nausea-associated receptors such as muscarinic, dopaminergic, and histaminic. The metabolites have stronger binding interactions than acetylcholine (ACh) for muscarinic M

Conflict of interest statement

The authors declare no competing financial interest.

References

  1. Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26 - PubMed
  2. Int J Clin Pharmacol Ther. 2001 Dec;39(12):517-28 - PubMed
  3. J Pharmacol Exp Ther. 2002 May;301(2):451-8 - PubMed
  4. Drugs. 1992;44 Suppl 4:1-16; discussion 66-9 - PubMed
  5. Cancer. 1992 Oct 1;70(7):2018-20 - PubMed
  6. Cancer Res. 1963 Sep;23:1390-427 - PubMed
  7. Pharm Res. 2003 Oct;20(10):1607-11 - PubMed
  8. Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3815-20 - PubMed
  9. Inflamm Res. 2004 Aug;53 Suppl 2:S154-8 - PubMed
  10. J Pharmacol Toxicol Methods. 2004 Nov-Dec;50(3):187-99 - PubMed
  11. Pharmacol Biochem Behav. 2005 May;81(1):211-9 - PubMed
  12. Nature. 2005 May 26;435(7041):519-22 - PubMed
  13. Nat Rev Drug Discov. 2006 Mar;5(3):219-34 - PubMed
  14. Drug Metab Pharmacokinet. 2006 Jun;21(3):238-44 - PubMed
  15. ChemMedChem. 2006 Aug;1(8):878-90 - PubMed
  16. Curr Pharm Des. 2006;12(28):3573-81 - PubMed
  17. J Chem Inf Model. 2006 Nov-Dec;46(6):2692-7 - PubMed
  18. J Am Chem Soc. 2007 Jan 31;129(4):867-72 - PubMed
  19. J Clin Pharmacol. 2007 May;47(5):579-88 - PubMed
  20. J Pharm Biomed Anal. 2008 May 12;47(1):47-58 - PubMed
  21. Cancer J. 2008 Mar-Apr;14(2):85-93 - PubMed
  22. Can Fam Physician. 2008 Jun;54(6):861-3 - PubMed
  23. Palliat Med. 2008 Oct;22(7):869-71 - PubMed
  24. J Am Soc Mass Spectrom. 2009 Feb;20(2):238-46 - PubMed
  25. Nat Protoc. 2009;4(1):1-13 - PubMed
  26. Nat Protoc. 2009;4(3):363-71 - PubMed
  27. Drug Metab Rev. 2009;41(4):573-643 - PubMed
  28. J Am Chem Soc. 2010 Jun 23;132(24):8489-95 - PubMed
  29. Toxicol Sci. 2010 Sep;117(1):144-51 - PubMed
  30. J Med Chem. 2010 Sep 9;53(17):6445-56 - PubMed
  31. Eur J Drug Metab Pharmacokinet. 1990 Oct-Dec;15(4):323-32 - PubMed
  32. Mol Pharmacol. 2011 May;79(5):855-65 - PubMed
  33. Med Res Rev. 2011 May;31(3):443-81 - PubMed
  34. J Am Chem Soc. 2011 May 25;133(20):7977-84 - PubMed
  35. Adv Exp Med Biol. 2010;709:vii-viii - PubMed
  36. Nature. 2011 Jun 22;475(7354):65-70 - PubMed
  37. J Pract Nurs. 2011 Spring;61(1):7-20 - PubMed
  38. Essays Biochem. 2011 Sep 7;50(1):161-78 - PubMed
  39. J Phys Chem B. 2012 Jan 12;116(1):532-41 - PubMed
  40. J Pharm Biomed Anal. 2012 Oct;69:106-24 - PubMed
  41. Acta Crystallogr D Biol Crystallogr. 2012 Aug;68(Pt 8):927-34 - PubMed
  42. PLoS One. 2012;7(9):e44316 - PubMed
  43. J Pharm Biomed Anal. 2013 Oct;84:309-22 - PubMed
  44. Pharmacol Ther. 2013 Apr;138(1):103-41 - PubMed
  45. Anticancer Drugs. 2013 Sep;24(8):810-7 - PubMed
  46. Support Care Cancer. 2013 Oct;21(10):2845-51 - PubMed
  47. Proc Jpn Acad Ser B Phys Biol Sci. 2013;89(6):226-56 - PubMed
  48. Breast Cancer Res Treat. 2013 Nov;142(1):101-7 - PubMed
  49. Int J Prev Med. 2013 Nov;4(11):1231-5 - PubMed
  50. Oncologist. 2014 Feb;19(2):127-34 - PubMed
  51. Xenobiotica. 2014 Sep;44(9):792-803 - PubMed
  52. Nutr Cancer. 2014;66(4):662-74 - PubMed
  53. J Mol Graph Model. 2014 Nov;54:1-9 - PubMed
  54. J Cell Biol. 2014 Nov 10;207(3):323-34 - PubMed
  55. Pharmacol Ther. 2015 May;149:1-123 - PubMed
  56. Cold Spring Harb Perspect Biol. 2015 Jan 05;7(1):a020412 - PubMed
  57. J Biomol Struct Dyn. 2015;33(10):2234-54 - PubMed
  58. FEBS J. 2015 Mar;282(6):1137-51 - PubMed
  59. Mol Divers. 2015 May;19(2):321-32 - PubMed
  60. Proteins. 2015 May;83(5):970-81 - PubMed
  61. Biochemistry. 2015 Mar 31;54(12):2149-59 - PubMed
  62. Asian Pac J Cancer Prev. 2015;16(15):6207-13 - PubMed
  63. ACS Chem Neurosci. 2016 Feb 17;7(2):185-95 - PubMed
  64. In Silico Pharmacol. 2015 Dec;3(1):6 - PubMed
  65. Nature. 2016 Mar 17;531(7594):335-40 - PubMed
  66. Neuropharmacology. 2016 Sep;108:220-8 - PubMed
  67. Auton Neurosci. 2017 Jan;202:18-27 - PubMed
  68. J Med Chem. 1989 Sep;32(9):2158-62 - PubMed
  69. Vet Immunol Immunopathol. 2016 Dec;182:29-36 - PubMed
  70. Crit Rev Oncol Hematol. 2017 Apr;112:113-125 - PubMed
  71. Pak J Pharm Sci. 2016 Nov;29(6):2079-2082 - PubMed
  72. Bioorg Med Chem Lett. 2017 Jul 15;27(14):3055-3059 - PubMed
  73. Chem Res Toxicol. 2017 Jul 17;30(7):1492-1507 - PubMed
  74. Int J Pharm. 2018 Oct 5;549(1-2):133-149 - PubMed
  75. J Pharm Biomed Anal. 2019 Feb 5;164:326-336 - PubMed
  76. J Pharm Sci. 2019 Jan;108(1):741-749 - PubMed
  77. Comput Biol Chem. 2018 Dec;77:318-330 - PubMed
  78. Cells. 2018 Nov 19;7(11):null - PubMed
  79. Proc Natl Acad Sci U S A. 1988 May;85(10):3580-4 - PubMed
  80. Biochem Pharmacol. 1973 Sep 1;22(17):2113-9 - PubMed
  81. Cancer Res. 1993 Nov 1;53(21):5121-6 - PubMed
  82. J Neurochem. 1996 Oct;67(4):1688-93 - PubMed
  83. Cancer Res. 1977 Aug;37(8 Pt 1):2597-602 - PubMed
  84. Br J Clin Pharmacol. 1997 Jun;43(6):633-7 - PubMed

Publication Types